Kendrick, Tony, Peveler, Robert, Longworth, Louise, Baldwin, David, Moore, Michael, Chatwin, Judy, Thornett, Andrew, Goddard, Jonathan, Campbell, Michael, Smith, Helen, Buxton, Martin and Thompson, Christopher (2006) Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial. British Journal of Psychiatry, 188 (4), 337-345. (doi:10.1192/bjp.188.4.337).
Abstract
Background The cost-effectiveness of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) has not been compared in a prospective study in primary care.
Aims To determine the relative cost-effectiveness of TCAs, SSRIs and lofepramine in UKprimary care.
Method An open-label, three-arm randomised trial with a preference arm. Practitioners referred 327 patients with incident depression.
Results No significant differences were found in effectiveness or cost-effectiveness. The numbers of depression-free weeks over12 months (on the Hospital Anxiety and Depression Scale) were 25.3 (95% CI 21.3–29.0) for TCAs, 28.3 (95% CI 24.3–32.2) for SSRIs and 24.6 (95% CI 20.6–28.9) for lofepramine. Mean health service costs per patient were £762 (95% CI 553–1059) for TCAs, £875 (95% CI 675–1355) for SSRIs and £867 (95% CI 634–1521) for lofepramine.Cost-effectiveness acceptability curves suggested SSRIs were mostcost-effective (with a probability of up to 0.6).
Conclusions The findings support a policy of recommending SSRIs as first-choice antidepressants in primary care.
This record has no associated files available for download.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.